MedPath

Octafluoropropane

Generic Name
Octafluoropropane
Brand Names
Definity, Luminity, Optison
Drug Type
Small Molecule
Chemical Formula
C3F8
CAS Number
76-19-7
Unique Ingredient Identifier
CK0N3WH0SR
Background

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Indication

Used as an ultrasound contrast imaging in cardiology and radiology.

Associated Conditions
-
Associated Therapies
-

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Not Applicable
Completed
Conditions
Colon Cancer
Liver Metastases
Interventions
Procedure: Dynamic contrast-enhanced ultrasound imaging
Device: Optical Tracking Device
Device: Electromagnetic Tracking Device
Drug: Perflutren
First Posted Date
2012-06-29
Last Posted Date
2022-06-10
Lead Sponsor
Stanford University
Target Recruit Count
34
Registration Number
NCT01631318
Locations
🇺🇸

Stanford University, Stanford, California, United States

Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram

Not Applicable
Conditions
Contrast Induced Acute Kidney Injury
Interventions
First Posted Date
2012-03-05
Last Posted Date
2013-12-19
Lead Sponsor
University of Virginia
Target Recruit Count
150
Registration Number
NCT01544036
Locations
🇺🇸

University of Virginia Health System, Charlottesville, Virginia, United States

Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

Phase 2
Completed
Conditions
Renal Cell Carcinoma
Interventions
First Posted Date
2010-02-04
Last Posted Date
2016-03-08
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
167
Registration Number
NCT01062178
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair

Completed
Conditions
Endoleaks
First Posted Date
2009-10-30
Last Posted Date
2024-04-12
Lead Sponsor
E. Peden, MD
Target Recruit Count
20
Registration Number
NCT01005212
Locations
🇺🇸

Houston Methodist Hospital; Department of Cardiovascular Surgery, Houston, Texas, United States

🇺🇸

Houston Methodist Hospital; Department of Cardiovascualr Surgery, Houston, Texas, United States

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure

Phase 4
Completed
Conditions
Pulmonary Heart Disease
Interventions
First Posted Date
2009-06-11
Last Posted Date
2020-11-24
Lead Sponsor
Lantheus Medical Imaging
Target Recruit Count
32
Registration Number
NCT00918866
Locations
🇺🇸

Cardiovascular Consultants, Kansas City, Missouri, United States

🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 5 locations

Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

Phase 1
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Definity
Other: medical chart review
First Posted Date
2008-02-29
Last Posted Date
2017-04-18
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
67
Registration Number
NCT00626873
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States

🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Detection of Coronary Stenosis With Intravenous Microbubbles

Not Applicable
Withdrawn
Conditions
Myocardial Reperfusion
Carotid Stenosis
Coronary Stenosis
Interventions
First Posted Date
2007-12-24
Last Posted Date
2023-11-29
Lead Sponsor
University of Nebraska
Registration Number
NCT00580580
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

The Silicone Study

Phase 3
Completed
Conditions
Proliferative Vitreoretinopathy
Retinal Detachment
First Posted Date
1999-09-24
Last Posted Date
2005-06-24
Lead Sponsor
National Eye Institute (NEI)
Registration Number
NCT00000140
© Copyright 2025. All Rights Reserved by MedPath